ProMIS Neurosciences is trading 11.45% up at $13.96 after management highlighted zero ARIA-E cases and favorable blinded biomarker trends from the PRECISE-AD Alzheimer’s study at the September 9 Cantor Global Healthcare Conference.
- No treatment-related serious adverse events, discontinuations, or dropouts were reported.
- Full 12-month results for the 128-patient study are expected in the first quarter of 2027.